This prospective clinical trial aims to investigate the impact of darolutamide in combination with standard-of-care androgen deprivation on physical activity, specifically step count, and its correlation with important markers of safety in vulnerable adults who screen positive by a brief geriatric assessment (GA) and metastatic hormone-sensitive prostate cancer.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-25; most recent amendment 2026-01-07.